Loading the peptide page…
Loading the peptide page…
The only GHRH analog FDA-approved today, and only to reduce excess belly fat in HIV lipodystrophy.
Last reviewed Oct 7, 2026 · How we rate evidence · Report an error
A 44-amino-acid GHRH analog approved (as Egrifta) to reduce excess abdominal fat in HIV patients with lipodystrophy. Strong randomized trial evidence; off-label use targets visceral fat and IGF-1.
Stimulates pituitary GH release through the GHRH receptor, raising IGF-1 and reducing visceral adipose tissue while preserving the natural pulse pattern.
Evidence
5/5
Phase 3 RCTs in HIV lipodystrophy led to FDA approval; off-label populations less studied.
Half-life
About 25–40 minutes
Known as
Egrifta, TH9507
Compare Tesamorelin with: SermorelinCJC-1295 (no DAC) + IpamorelinIpamorelinIGF-1 LR3or any other →
Approved, with large trialsRegulators approved it after big randomized controlled trials (RCTs), in which people are randomly given the drug or a placebo.
Phase 3 RCTs in HIV lipodystrophy led to FDA approval; off-label populations less studied. How we rate evidence
~15–18% visceral fat reduction over 26 weeks in Phase 3 trials.
Dose-dependent, predictable response.
Small trials in older adults show modest effects.
“Anecdotal” means reported by users, not shown in controlled trials. Sources
Not recommendations. These are commonly cited ranges, shown so you can see what real-world use looks like.
| Plan | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
| Label dose (Egrifta SV) FDA label: 1.4 mg once daily (Egrifta SV). Egrifta WR (2025) is 1.28 mg daily from a weekly-mixed vial. The original 2010 Egrifta was 2 mg daily. | 1.4 mg | Once daily | Ongoing under physician care | Subcutaneous, abdomen |
| Community low-dose | 1 mg | Once daily, bedtime | 12 weeks | Subcutaneous |
Set up for Tesamorelin. Switch vial size any time. Educational math only, not dosing advice.
At a common mix of 10 mg of Tesamorelin in 2 mL of water (5 mg/mL), these commonly reported doses come to the following on a U-100 insulin syringe (100 units = 1 mL). They are examples of the arithmetic, not recommendations.
| Reported plan | Dose | Draw to | Volume |
|---|---|---|---|
| Label dose (Egrifta SV) | 1.4 mg | 28 units | 0.28 mL |
| Community low-dose | 1 mg | 20 units | 0.2 mL |
Concentration (mg/mL) = vial mg ÷ mL of water; units = dose (mg) ÷ concentration × 100. A different vial size or amount of water changes every number above.
Amino Club sells Tesamorelin as a research chemical. Its listings are research-use-only and not for human use; we show them for price tracking and their published lab reports.
Research-use-only listing — not for human use.
40% off through our link (code MYPEPSINFO applies automatically), until Dec 31, 2026.
| Size | Price | Per mg | Stock | Latest COA |
|---|---|---|---|---|
| 10 mg | $41.99 | $4.20 | In stock | 99.61% pure, lot TES0003 ILS Labs, tested Jul 30, 2026 |
List price, checked daily since Oct 7.
| Oct 7, 2026 | $69.99 | |
| Oct 8, 2026 | $69.99 | |
| Oct 9, 2026 | $69.99 | |
| Oct 10, 2026 | $69.99 | |
| Oct 11, 2026 | $69.99 | |
| Oct 12, 2026 | $69.99 | |
| Oct 13, 2026 | $69.99 | |
| Oct 14, 2026 | $69.99 | |
| Oct 15, 2026 | $69.99 | |
| Oct 16, 2026 | $69.99 | |
| Oct 17, 2026 | $69.99 | |
| Oct 18, 2026 | $69.99 | |
| Oct 19, 2026 | $69.99 | |
| Oct 20, 2026 | $69.99 | |
| Oct 21, 2026 | $69.99 | |
| Oct 22, 2026 | $69.99 | |
| Oct 23, 2026 | $69.99 | |
| Oct 24, 2026 | $69.99 | |
| Oct 25, 2026 | $69.99 | |
| Oct 26, 2026 | $69.99 | |
| Oct 27, 2026 | $69.99 | |
| Oct 28, 2026 | $69.99 | |
| Oct 29, 2026 | $69.99 | |
| Oct 30, 2026 | $69.99 | |
| Oct 31, 2026 | $69.99 | |
| Nov 1, 2026 | $69.99 |
HPLC purity from each published lab report; lowest 98.82%.
| May 29, 2026 | 98.82% | lot TES0001 |
| Jun 10, 2026 | 99.61% | lot TES0002 |
| Jul 30, 2026 | 99.61% | lot TES0003 |
Amino Club list prices as of Nov 1, 2026; sale prices include the 40% applied through our link. Multi-buy: 2+ units 5% off, 3+ units 7.5% off, 10+ units 40% off. Prices change; confirm on the listing.
An email when it’s back in stock, its price drops, a sale starts, or its FDA or WADA status changes.
Affiliate link: we may earn a commission at no cost to you. Disclosure
All Tesamorelin lab reports, lot by lot →
Diluent: Sterile water or bacteriostatic water. Follow product instructions — the approved Egrifta uses a specific sterile-water process.
Amazon affiliate links. Disclosure
Powder
Freezer / fridge
Keep sealed vial in the freezer (−20 °C) for long-term storage; fridge (2–8 °C) is fine for a few weeks. Keep dry and out of light.
After mixing
~14 days
Refrigerate at 2–8 °C. Never freeze after mixing. Keep upright, capped, and out of light.
Travel
Keep cool
Short trips at room temperature are generally fine for powder; keep mixed vials cold.
Approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Not approved for general weight loss or anti-aging; research vials are not the approved drug.
Regulations change often — verify with the FDA, EMA, MHRA, Health Canada, TGA and WADA before acting.
No. Egrifta is a manufactured, regulated drug with controlled quality. A research vial is not the approved product.
It depends on the mix. At a common mix of 10 mg of Tesamorelin in 2 mL of water (5 mg/mL), 1.4 mg is 28 units (0.28 mL) on a U-100 insulin syringe. The formula is dose in mg ÷ concentration in mg/mL × 100. Change the vial size or water in the calculator and the units update. This is math, not a dose recommendation.
Sterile water or bacteriostatic water. Follow product instructions — the approved Egrifta uses a specific sterile-water process. A common mix is 10 mg + 2 mL, which gives 5 mg/mL. Less water makes a stronger mix and fewer units per dose; more water makes a weaker mix and more units. Pick the amount that lands your dose on an easy-to-read line.
Refrigerate at 2–8 °C. Never freeze after mixing. Keep upright, capped, and out of light. Plan on about 14 days once it is mixed, and discard it sooner if it turns cloudy or has particles. The calculator shows how long a vial lasts at your dose and flags a vial that outlasts its shelf life.
Evidence rating (5/5): Phase 3 RCTs in HIV lipodystrophy led to FDA approval; off-label populations less studied.
Legal status: Approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Not approved for general weight loss or anti-aging; research vials are not the approved drug.
See something wrong or out of date? Report an error and we’ll check it against the sources. How we review pages